Research Highlights from the 2014 Genitourinary Cancers Symposium

January 28, 2014
Lindsay Dudbridge, ASCO staff

This weekend, doctors and researchers from around the world will be gathering in San Francisco, California to discuss the latest advances in the diagnosis, treatment, and management of genitourinary(GU) cancers, including cancers of the bladder, kidney, prostate, and testis, as well as less common cancers, such as those of the penis, ureters, and other urinary organs. In this podcast, Charles J. Ryan, MD, a GU cancers expert on the ASCO Cancer Communications Committee, provides an overview of four important studies that will be featured at the meeting.

This is a prerecorded audio podcast, and it can be listened to online or downloaded to your computer. A transcript of this podcast is also available. For more information, visit the Cancer.Net podcast page.

Highlights from these studies include:

Enzalutamide, a Type of Hormone Therapy, Lengthens the Lives of Men with Metastatic Castration-Resistant Prostate Cancer. Results from this study show that a new type of hormone therapy, enzalutamide, slows or stops cancer growth, delaying the need for chemotherapy by 17 months.

Fewer Men Dying of Prostate Cancer 10 and 15 Years After Combined Treatment of Radiation Therapy and Anti-Androgen Therapy. Updated results from a study out of Norway and Sweden show that the combination of radiation therapy and anti-androgen therapy more than halves the deaths from prostate cancer 10 and 15 years after treatment.

Common Drug Helps Patients with Kidney Cancer and High Blood Pressure Live Longer. In this study, researchers find that a common type of medication used for high blood pressure lengthens the lives of patients with kidney cancer that has spread by nine months when it is used to manage their high blood pressure while they are receiving cancer treatment.

One in Five Clinical Trials for Adults with Cancer Never Finish – New Study Examines the Reasons. A review of studies from shows 1 in 5 cancer clinical trials never finishes, most commonly because enough patients could not participate in the study.

Share your thoughts on this blog post on Cancer.Net's Facebook and Twitter.